INTRODUCTION
============

Osteoarthritis (OA) is the most common joint disease. Currently, OA affects more than 20 million Americans, and this number is expected to double over the next 2 decades [@b1],[@b2]. In Britain, a study of those age ≥85 years showed that 52% were affected by OA [@b3]. Risk factors include obesity, injuries, surgery, and occupational load [@b4],[@b5]. Obesity and OA share pathogenic features; the development of one disease increases the risk of the other [@b6]--[@b8]. As the average weight of the population increases, severe health consequences will ensue [@b9]. The burden of obesity includes an increased number of nonfatal diseases, including OA imposing substantial medical costs from treatment and productivity losses [@b10]. Accordingly, obesity must be taken seriously in any discussion of health [@b11], including that of the joints [@b2],[@b10].

Current treatments can effectively target obesity in patients with coexistent obesity and OA, with short-term efficacy of weight loss comparable to that of a joint replacement [@b12]. A meta-regression analysis showed that function in obese knee OA patients could be significantly improved when weight was reduced more than 5.1%, at the rate of 0.24% per week, indicating that physical function of overweight patients with knee OA improves even after a moderate weight reduction regimen [@b13]. Accordingly, the Osteoarthritis Research Society International (OARSI) guidelines strongly recommended that overweight OA patients with lower extremity OA lose weight and maintain a lower weight level [@b14]--[@b16].

There are no definitive data on whether weight loss is beneficial for reducing OA progression [@b17]. However, available results from different study designs support the notion that intensive dietary-induced weight loss and exercise interventions may slow disease progression [@b8]. Weight loss may be induced by using a low-energy diet strategy [@b18]. Continuous dietary counseling is recommended to maintain weight loss, but in OA patients reinforcements of other activities for pain and disability improvement after weight loss may also be desirable. Exercise is recommended to improve pain and disability [@b19]; exercise is also recommended as a means of losing weight and maintaining weight loss in the general population when it is combined with dietary change [@b20]. Weight loss and exercise for obese OA patients are recommended by most guidelines [@b21]. However, the effects of continuous dietary counseling and exercise on weight loss maintenance and clinical outcomes remain to be clarified.

This study aimed to compare the symptomatic outcomes of 1) one year of continuous dietary support from a dietician, and 2) one year of a specialized knee exercise program with 3) a "no attention" control group, all after an initial 16-week weight loss program to obtain a clinically significant weight loss in obese knee OA patients.

###### Significance & Innovations

This study is important in the sequence required to provide the evidence base for justifying weight loss and maintenance in osteoarthritis (OA) management.This trial showed that following an intensive 16-week dietary weight loss run-in program, pain reduction was maintained similarly in all groups with no difference between continuous dietary consultancy, knee exercises, and no treatment.Compliance with the dietary program was better than with the knee-exercises program; the obese with knee OA could not be induced to exercise as instructed. A dietary program with partial use of formula diet and dietitian support may prevent subsequent weight gain for up to 1 year.Diet and knee exercises both result in maintenance of the primary outcome (symptoms) and the choice of one or the other has to be based on other factors, e.g., patient preferences.

PATIENTS AND METHODS
====================

Trial design and participants
-----------------------------

The CAROT study (Influence of Weight Loss or Exercise on Cartilage in Obese Knee Osteoarthritis Patients Trial) was designed as a pragmatic randomized controlled trial with blinded outcome assessors. Participants were prescreened via telephone using a series of standard questions concerning eligibility and recruited November 2007 through August 2008 at the Department of Rheumatology, Frederiksberg Hospital, Denmark. The inclusion and exclusion criteria for the study attempted to ensure that the therapy would exclude as few participants as possible from participation and would be directly relevant to health care practitioners [@b22]. Individuals age ≥50 years and above with confirmed knee OA based on clinical symptoms, including pain, and on standing radiographs in at least 1 joint compartment were eligible for inclusion [@b23]. All participants were obese, as defined by a body mass index (BMI) ≥30 kg/m^2^. Participants were excluded if they had any of the following: lack of motivation to lose weight, inability to speak Danish, planned antiobesity surgery, total knee alloplasty (TKA), or receiving pharmacologic therapy for obesity. In the case of both knees having OA symptoms, the worst knee was defined as the index knee and participants asked to concentrate their answers accordingly. Participants were asked not to change any medication or nutritional supplements during the study. All participants gave written informed consent for the study, which was approved by the ethics committee of the Capital Region of Denmark \[H-B-2007-088\] and registered with [ClinicalTrials.gov](http://ClinicalTrials.gov) (NCT00655941). The procedures followed were in accordance with the ethical standards of the responsible committee on human experimentation (institutional and national) and with the Helsinki Declaration of 1975, as revised in 2000.

Randomization and allocation concealment
----------------------------------------

All participants entered an initial 16-week intensive dietary therapy, inducing a major weight loss [@b24]--[@b27], after which participants were informed about the group allocation over the following 52 weeks; patients were randomly assigned with the use of minimization to one of 3 subsequent treatment groups with an equal allocation ratio (1:1:1) [@b28],[@b29]. The participants were stratified according to sex, body weight at baseline, and weight loss (first 8 weeks of phase 1). The concealed allocation was done on the basis of all the participants entering the study at baseline. Each randomization list was drawn up by the biostatistician (RC) and given to the secretariat at the Parker Institute who subsequently informed the participant where to meet in the maintenance period, securing a concealed allocation. The random assignment prevented knowledge of forthcoming allocations by study participants and personnel recruiting participants to the trial.

Interventions
-------------

Initially, all participants went through a 16-week intensive dietary weight loss intervention, which has been described in detail previously (see Supplementary Appendix A, available in the online version of this article at <http://onlinelibrary.wiley.com/doi/10.1002/acr.22504/abstract)> [@b25].

### Dietary program

The objective of the 1-year trial weight loss maintenance program was to focus on long-term lifestyle modifications and help participants reach their weight loss goals. During the year-long maintenance phase, the participants met weekly at the dietary unit at the Parker Institute, attending sessions that lasted approximately 1 hour (1 session per week, for a total 52 possible sessions). The participants were weighed, and formula products were handed out. Participants were advised to use 1 formula product a day to enhance weight loss [@b30]. They could choose between a liquid shake and a snack bar, which were provided free of charge by the manufacturer (The Cambridge Weight Plan) [@b31]. Details of the visits are given in Supplementary Appendix B (available in the online version of this article at <http://onlinelibrary.wiley.com/doi/10.1002/acr.22504/abstract>).

### Exercise program

Participants underwent a 3-day/week exercise program consisting of a warm-up phase (10 minutes), a circuit-training phase (45 minutes), and a cool down/stretching phase (5 minutes). The exercise intervention was divided into 4 periods of 12 weeks and 1 period of 4 weeks (total 52 weeks). The idea was to gradually translate the exercise from supervised facility-based exercises to unsupervised home-based exercises. Details of the exercise program are given in Supplementary Appendices A and B, available in the online version of this article at <http://onlinelibrary.wiley.com/doi/10.1002/acr.22504/abstract>).

Control group program
---------------------

The control group served as a usual care comparison group and no attention was provided to the participants after the first 16 weeks of therapy. However, all patients allocated to this group were informed that they would be contacted after 52 weeks and would then have an option to enter another active intervention program, i.e., the LIGHT (long-term intervention with group-wise dietary consulting supported by meal replacements maintaing weight loss in patients with concomitant obesity and knee osteoarthritis) study (NCT00938808).

Outcome measures
----------------

The co-primary outcome of this trial was the patients\' self-reported pain on a 100-mm visual analog scale (VAS) and the number of patients responding according to the Outcome Measures in Rheumatology (OMERACT)--OARSI responder criteria [@b32]. The 3 items of the OMERACT-OARSI responder criteria were assessed using 100-mm VAS with separate results for pain, disability, and global evaluation by the patient. The secondary outcomes were other patient-reported outcomes for symptoms of knee OA, as perceived by patients prior to and after intervention (weeks 0, 16, and 68), obtained via the 5 subscales of the Knee injury and Osteoarthritis Outcome Score (KOOS) questionnaires [@b33]; the 5 subscales are pain, other symptoms, function in daily living, function in sport and recreation, and knee-related quality of life. The KOOS subscales are normalized, with 100 indicating no knee problems and 0 indicating extreme knee problems [@b33]. At all time points, the participants also reported health-related quality of life [@b34] using the Short-Form 36 (SF-36) health survey [@b35]. From the taxonomy of the SF-36, having 3 levels, our objective was to explore the third level, with 2 summary measures that aggregate scales: the physical component summary and the mental component summary measure [@b36]. We applied the Danish version of the SF-36 health survey [@b37].

### Radiographs, anthropometry, and gait speed

Bi-plane, weight-bearing, semiflexed nonfluoroscopic radiographs were taken of both knees at a 15° knee flexion at baseline and at 68 weeks. Body composition was evaluated by full body dual x-ray absorptiometry \[DXA\] scans (LUNAR DPX-IQ, Lunar Corporation). Physical function was assessed by the 6-minute walk test (6MW) [@b38], which was performed indoors on a predefined 100-meter route. The patients walked the route as many times as possible in 6 minutes (i.e., at maximal speed). Results of the 6MW test were recorded as meters covered in 6 minutes.

### Adverse events

Adverse events were noted using nonleading questions at all clinic visits, including at baseline. All events were coded according to the Medical Dictionary for Regulatory Activities as currently required by all regulatory authorities, including the US Food and Drug Administration and the European Agency for the Evaluation of Medicinal Products. Routine laboratory tests, including measurement of serum glucose levels for estimating effects on glucose homeostasis and administration of liver function tests, were performed at baseline and together with each of the subsequent outcome assessments (i.e., at weeks 8, 16, and 68).

Statistical analysis
--------------------

CAROT was designed as a superiority trial. The sample size was calculated to detect differences between the 2 maintenance groups after 68 weeks, corresponding to a moderate effect size in the VAS pain scores for the pairwise comparison of the control group with each of the 2 competing maintenance regimens. A sample size of 64 per group would be required to obtain a power of at least 80% to detect a mean difference of 12.5 mm by VAS. Therefore, the 192 knee OA patients were included in the intent-to-treat (ITT) population (see Supplementary Appendix A, available in the online version of this article at <http://onlinelibrary.wiley.com/doi/10.1002/acr.22504/abstract>). All confirmatory data analyses were carried out according to a prespecified analysis plan. Analyses were done applying SAS software (version 9.2). At week 68, the diet or exercise groups were compared with the control group by analyses of covariance (ANCOVA) for mean changes from baseline in all the continuous outcome data. The model included the change as the dependent variable, with treatment group as a main effect and the baseline score as an additional covariate. The proportion of patients responding to therapy (OMERACT-OARSI and \>10% weight loss) and those reporting adverse events were analyzed; the chi-square test was performed to evaluate the differences between the diet, exercise, and control groups.

The ITT population was defined as all individuals entering the initial weight loss phase. To preserve the ITT population, missing data were replaced using the baseline observation carried forward technique, an imputation technique considered conservative in weight loss trials even if data are not missing at random [@b39]. This assumption would imply, for symptom scores, that the patients had no improvement from entering the study (i.e., a conservative estimate). Further, we elaborated on different scenarios, for the purpose of sensitivity analyses, using different aspects of analysis populations and imputation techniques to see if the results were robust to different (plausible) assumptions about the missing data [@b40]. The estimates corresponding to the "as observed population" are available in Supplementary Appendix C (available in the online version of this article at <http://onlinelibrary.wiley.com/doi/10.1002/acr.22504/abstract>).

RESULTS
=======

Participant flow and characteristics
------------------------------------

The total number of persons pre-screened via telephone during the 9 months recruitment period was 388 ([Figure 1](#fig01){ref-type="fig"}). Of these, 187 (48%) were ineligible, and 9 (2%) declined to participate at the screening visit. The patient characteristics of the 192 individuals included as the ITT population are presented in Table[1](#tbl1){ref-type="table"}. The typical participant was a 62-year-old woman, with a BMI of 37 kg/m^2^, representing 25--30 kg of excess body weight. Table[1](#tbl1){ref-type="table"} also shows the Kellgren/Lawrence scores and the KOOS scores of the participants. Of the 192 patients, 170 (89%) had bilateral knee OA, with 21 (12%) having a TKA on the contralateral knee. Of the 192 patients being randomized, 175 (91%) completed the study of the first (16-week) phase [@b24]. The 17 study participants who did not complete the first phase of the study were not different from those who remained in terms of age, sex, BMI, initial radiographic score, knee pain, or physical function [@b24]. During the following 1-year symptom and weight maintenance program, 16 of the 175 patients (9.1%) who had completed the first phase dropped out of the study ([Figure 1](#fig01){ref-type="fig"}). The dropout rate was significantly lower in the D group that was assigned the diet maintenance program (1 patient of 56, 1.8%) than in participants assigned to the C group (control group) program (9 patients of 61, 14.8%; *P* = 0.0078) and the E group (exercise maintenance) program (6 patients of 58, 10.3%; *P* = 0.050). There was an overall completion rate in favor of the dietary maintenance program when comparing the attrition rate in the 3 groups (χ^2^ = 6.06, 2 df, *P* = 0.048).

![Study flow diagram of enrollment, randomization, and followup. Ineligibility at screening was mostly due to young age or too low body mass index for participation. ITT = intent-to-treat; VLED = very low energy diet; LED = low energy diet; TKA = total knee arthroplasty.](acr0067-0640-f1){#fig01}

###### 

Baseline characteristics of the patients[\*](#tf1-1){ref-type="table-fn"}

  Variable                                                                          Control (n = 64)      Diet (n = 64)        Exercise (n = 64)          
  --------------------------------------------------------------------------------- --------------------- -------------------- -------------------- -- -- --
  Age, years                                                                        61.7 ± 6.8            63.0 ± 6.5           62.9 ± 5.8                 
  Female sex, no. (%)                                                               51 (80)               52 (81)              52 (81)                    
  Height                                                                            166 ± 9               166 ± 8              166 ± 8                    
  Duration of OA symptoms, median (IQR) years                                       8.0 (4.5--13.0)       8.0 (3.8--10.0)      9.5 (4.8--15.0)            
  K/L radiographic reading, no. (%)                                                                                                                       
   I                                                                                4 (6)                 3 (5)                10 (16)                    
   II                                                                               24 (38)               24 (39)              23 (36)                    
   III                                                                              25 (39)               22 (35)              21 (33)                    
   IV                                                                               11 (17)               13 (21)              10 (16)                    
  K/L radiographic reading, 0--4                                                    2.7 ± 0.8             2.7 ± 0.9            2.5 ± 0.9                  
  Joint space width, median (IQR) mm[†](#tf1-2){ref-type="table-fn"}                2.0 (0.0--3.6)        2.5 (0.0--3.8)       2.6 (0.0--3.8)             
  Anthropometric and gait speed variables                                                                                                                 
   Body weight, kg                                                                  105.0 ± 16.1          103.6 ± 14.8         101.0 ± 14.0               
   Body mass index, kg/m^2^                                                         37.9 ± 5.3            37.6 ± 4.5           36.5 ± 4.4                 
   Lean body mass, gm                                                               51,309.3 ± 9,348.4    51,053.2 ± 8,447.0   50,266.0 ± 8,511.1         
   Fat mass, gm                                                                     48,028.4 ± 10,381.3   47,353.3 ± 9,233.7   45,748.5 ± 9,107.5         
   Six-minute walk, meters                                                          443.19 ± 91.44        439.87 ± 74.60       446.92 ± 94.27             
  KOOS, 0--100[‡](#tf1-3){ref-type="table-fn"}                                                                                                            
   Pain                                                                             54.3 ± 16.2           59.1 ± 15.7          58.5 ± 16.3                
   Symptoms                                                                         58.8 ± 18.1           62.0 ± 15.0          61.3 ± 18.1                
   Function in daily living                                                         58.3 ± 16.6           60.9 ± 18.7          60.5 ± 17.0                
   Function in sport and recreation                                                 22.1 ± 19.4           21.3 ± 18.7          24.5 ± 21.6                
   Knee-related quality of life                                                     36.1 ± 15.3           38.4 ± 16.8          40.0 ± 17.3                
  Questions applicable for OMERACT-OARSI response[§](#tf1-4){ref-type="table-fn"}                                                                         
   VAS pain, 0--100                                                                 46.7 ± 19.7           39.5 ± 21.3          43.6 ± 20.0                
   VAS disability, 0--100                                                           47.7 ± 21.9           42.1 ± 23.4          41.5 ± 21.8                
   VAS patient global assessment, 0--100                                            37.3 ± 24.3           32.0 ± 21.9          34.0 ± 22.9                
  SF-36 health survey                                                                                                                                     
   Mental component summary, 0--100                                                 52.4 ± 13.3           54.7 ± 11.2          53.2 ± 10.4                
   Physical component summary, 0--100                                               33.5 ± 9.0            33.7 ± 8.1           34.1 ± 9.1                 

Values are the mean ± SD unless indicated otherwise. OA = osteoarthritis; IQR = interquartile range; K/L = Kellgren/Lawrence; KOOS = Knee Injury and Osteoarthritis Outcome Score; OMERACT = Outcome Measures in Rheumatology; OARSI = Osteoarthritis Research Society International; VAS = visual analog scale; SF-36 = Short Form 36 health survey.

For joint space width there were a number of images that were not possible to evaluate; estimates are based on n = 61 for control, n = 53 for diet, and n = 59 for exercise.

Lower scores indicate more severe disease.

Higher scores indicate more severe disease.

Changes in body weight and compliance to therapy
------------------------------------------------

As presented in [Figure 2](#fig02){ref-type="fig"}, all 3 randomized groups from the ITT population, but especially the D group, succeeded in maintaining weight loss after 1 year of maintenance therapy. Group D, which underwent the continuous dietary maintenance program, had an average weight change at 68 weeks from baseline of −11.0 kg (95% confidence interval \[95% CI\] −12.8, −9.1 kg), whereas the weight change in the exercise group was −6.2 kg (95% CI −8.1, −4.4 kg), and the control group had an average weight change of −8.2 kg (95% CI −10.1, −6.4 kg) (see Table[2](#tbl2){ref-type="table"}). This comparison is illustrated in [Figure 2](#fig02){ref-type="fig"}, with a statistically significant interaction between group and time (*P* \< 0.0001). After 68 weeks, the dietary maintenance program was more effective in maintaining lower body weight than both the exercise group (difference −4.7 kg \[−7.4, −2.1 kg\]; *P* = 0.0005) and the control group (difference −2.7 kg \[−5.4, −0.1 kg\]; *P* = 0.043). There was no statistically significant difference between the exercise and control groups (*P* = 0.14). In terms of weight loss responders, there was also a statistically significant difference between groups (*P* = 0.002); more patients randomized to the dietary maintenance program successfully lost more than 10% of their body weight from baseline (55% \[42--67%\]), than did the exercise group (27% \[16--37%\]; *P* = 0.00072) and the control group (31% \[20--43%\]; *P* = 0.0058).

![Changes in body weight over time were explored using a repeated-measures analysis of covariance (via PROC MIXED): a factor for group, a factor for time, and a factor for the interaction between them. The outcome at baseline was applied as covariate. Values are least squares (LS) means and error bars indicate SE of the LS means.](acr0067-0640-f2){#fig02}

###### 

Change in outcome measures from baseline at 68 weeks[\*](#tf2-1){ref-type="table-fn"}

  Outcome variable                                                     Control (n = 64)               Diet (n = 64)                    Exercise (n = 64)               *P*
  -------------------------------------------------------------------- ------------------------------ -------------------------------- ------------------------------- -------
  OMERACT-OARSI response, no. (%)                                      33 (52)                        32(50)                           26(41)                          0.407
  VAS pain, mm                                                         −5.5 (−10.5, −0.5)             −6.1 (−11.1, −1.1)               −5.6 (−10.5, −0.6)              0.982
  VAS disability, mm                                                   −9.0 (−14.4, −3.6)             −7.5 (−12.8, −2.1)               −7.6 (−13.0, −2.2)              0.910
  VAS patient global assessment, mm                                    −6.1 (−11.1, −1.1)             −5.1 (−10.1−0.1)                 −4.6 (−9.6, 0.4)                0.916
  Weight change, kg                                                    −8.23 (−10.09, −6.36)          −10.96 (−12.83, −9.09)           −6.24 (−8.11, −4.38)            0.002
  Weight change, % change from baseline                                −7.84 (−9.59, −6.10)           −10.79 (−12.53, −9.05)           −6.17 (−7.91, −4.42)            0.001
  Major weight loss (\>10%), no. (%)                                   20 (31)                        35 (55)                          17 (27)                         0.002
  Body mass index, kg/m^2^                                             −2.9 (−3.6, −2.2)              −4.0 (−4.7, −3.3)                −2.3 (−3.0, −1.6)               0.003
  Lean body mass, gm                                                   −1,168.9 (−1,614.7, −723.1)    −1,010.3 (−1,455.9, −564.7)      −873.7 (−1,323.2, −424.2)       0.655
  Fat mass, gm                                                         −5,978.1 (−7,564.9, 4,391.4)   −8,984.9 (−10,569.0, −7,400.7)   −4,796.6 (−6,398.0, −3,195.3)   0.001
  Six-minute walk, meters                                              22.89 (7.900, 37.889)          37.519 (22.757, 52.281)          38.478 (23.715, 53.240)         0.266
  Joint space width, mm[†](#tf2-2){ref-type="table-fn"}                0.0 (−0.1, 0.1)                −0.1 (−0.2, 0.1)                 −0.1 (−0.3, 0.0)                0.543
  Joint space width, median (IQR) mm[‡](#tf2-3){ref-type="table-fn"}   0.0 (0.0--0.1)                 0.0 (−0.1, 0.1)                  0.0 (0.0, 0.0)                  0.651
  KOOS, score 0--100[§](#tf2-4){ref-type="table-fn"}                                                                                                                   
   Pain                                                                8.7 (4.9, 12.4)                7.6 (3.8, 11.3)                  6.8 (3.1, 10.5)                 0.791
   Symptoms                                                            5.9 (2.2, 9.6)                 7.4 (3.6, 11.1)                  4.5 (0.8, 8.2)                  0.565
   Function in daily living                                            6.2 (2.7, 9.8)                 8.3 (4.7, 11.8)                  8.4 (4.8, 11.9)                 0.640
   Function in sport and recreation                                    4.7 (0.3, 9.1)                 5.8 (1.4, 10.2)                  6.4 (2.0, 10.8)                 0.860
   Knee-related quality of life                                        5.4 (1.7, 9.2)                 8.2 (4.5, 11.9)                  5.8 (2.1, 9.5)                  0.538
  Short-Form 36[¶](#tf2-5){ref-type="table-fn"}                                                                                                                        
   Mental component summary                                            1.3 (−0.5, 3.2)                −0.3 (−2.1, 1.6)                 0.1 (−1.7, 2.0)                 0.455
   Physical component summary                                          4.4 (2.5, 6.4)                 5.5 (3.5, 7.4)                   3.8 (1.9, 5.7)                  0.472

Values for the continuous data are the least squares mean (95% confidence interval), for the measured change from baseline to the followup assessment. Dichotomous data were analyzed using chi-square statistics. Data were analyzed using analysis of covariance: a factor for group, and the outcome variable at baseline was applied as covariate.

For joint space width there were a number of images that were not possible to evaluate; estimates are based on n = 61 for control, n = 53 for diet, and n = 59 for exercise.

Analyzed using a 1-factor analysis of variance with rank scores in each group.

A normalized score (100 indicating no symptoms and 0 indicating extreme symptoms).

A normalized score (100 indicates best health outcome and 0 indicates very poor health outcome).

During the 52 weeks, the median number of attendances at the dietary session was 32 of 52 possible (61.5%), whereas medical compliance with the facility-based exercise sessions was 7 attendances of 52 possible (13.5%). The median-reported, home-based exercise completion was 4 of 109 anticipated home sessions (4%).

Outcome measures
----------------

Across groups, all patients had a reduction in VAS pain after 68 weeks (*P* \< 0.03; within group analyses) independently of the group to which they were randomized to follow after the 16 weeks of clinically significant changes [@b24]. There were, however, no differences in pain reduction between groups (*P* = 0.98 by ANCOVA). Table[2](#tbl2){ref-type="table"} presents data for the pain reduction in the VAS (mm) after 68 weeks in the diet group (−6.1 mm \[95% CI −11.1, −1.1 mm\]), the exercise group (−5.6 mm \[95% CI −10.5, −0.6 mm\]), and the control group (95% CI −5.5 mm \[−10.5, −0.5 mm\]). As indicated from the overall ANCOVA, there was no difference between any of the groups after 68 weeks (*P* \> 0.86). The observed OMERACT-OARSI success rates were 50% (38--62%) for the diet group, 41% (29--53%) for the exercise group, and 52% (39--64%) for the control group (Table[2](#tbl2){ref-type="table"}). The OMERACT-OARSI response rates were successfully maintained across groups, which may be part of the reason for lack of statistically significant difference between the groups (*P* = 0.41).

### Secondary outcomes and adverse events

The occurrence of radiographic progression was assessed from the change in joint space width (i.e., joint space narrowing) after 68 weeks. Only paired images fully valid for interpretation by decision of the radiologist were analyzed, without any statistically significant differences between groups. Among all the other secondary outcomes, some were explored in more detail according to the prespecified statistical analysis plan. When we explored in greater depth the differences in weight loss across groups (*P* = 0.002 by ANCOVA), this finding was supported by the anthropometric measures from DXA scans of whole body composition in terms of loss of fat mass (*P* = 0.001 by ANCOVA), but not in loss of lean body mass (*P* = 0.65 by ANCOVA). The diet group lost significantly more fat mass than did both the control group (−3006.8 gm \[−5247.7, −765.8 gm\]; *P* = 0.0088) and the exercise group (−4188.2 gm \[−1934.0, −6442.4 gm\]; *P* = 0.0003). In contrast, there was no statistically significant difference in loss of fat mass between the exercise and control groups (*P* = 0.30). As presented in Table[2](#tbl2){ref-type="table"}, there was no statistical difference between the loss in lean body mass between the diet and control groups (*P* = 0.62), diet and exercise groups (*P* = 0.67), or exercise and control groups (*P* = 0.36). Table[3](#tbl3){ref-type="table"} presents all the adverse events, from mild to moderate, reported in each group from week 16 through week 68. No clinically important events or changes in laboratory tests were seen in any of the groups (data not shown).

###### 

Adverse events among patients reporting on various constructs of potential side effects after 68 weeks

                                                    Control   Diet   Exercise                                 
  ------------------------------------------------- --------- ------ ---------- ---- ---- ---- ---- ---- ---- ---------------------------------------
  Abdominal and intestinal symptoms                                                                           
   Nausea                                           52        1      2          55   3    5    52   8    15   0.036[†](#tf3-2){ref-type="table-fn"}
   Diarrhea                                         51        4      8          55   3    5    52   6    12   0.512[†](#tf3-2){ref-type="table-fn"}
   Constipation                                     52        8      15         55   9    16   52   7    13   0.914
   Flatulence                                       52        14     27         55   19   35   52   10   19   0.204
   Epigastric pain                                  52        1      2          55   6    11   52   7    13   0.082[†](#tf3-2){ref-type="table-fn"}
   Vomiting                                         52        1      2          55   3    5    52   4    8    0.444[†](#tf3-2){ref-type="table-fn"}
   Abdominal pain                                   52        3      6          55   6    11   52   6    12   0.622[†](#tf3-2){ref-type="table-fn"}
   Heartburn                                        51        3      6          55   3    5    52   9    17   0.083[†](#tf3-2){ref-type="table-fn"}
   Biliary symptoms                                 52        0      0          54   2    4    51   4    8    0.103[†](#tf3-2){ref-type="table-fn"}
  Musculoskeletal symptoms                                                                                    
   Cramps                                           49        8      16         54   6    11   52   7    13   0.742
   Joint pain                                       51        12     24         55   15   27   52   12   23   0.858
   Back pain                                        50        10     20         54   11   20   52   6    12   0.403
   Swollen joints                                   51        11     22         55   11   20   52   10   19   0.956
   Sciatic pain                                     51        9      18         55   4    7    52   7    13   0.270
  Central nervous system and psychiatric symptoms                                                             
   Dizziness                                        52        8      15         55   7    13   52   10   19   0.651
   Headache                                         52        5      10         53   6    11   51   12   24   0.095
   Anxiety                                          52        2      4          53   3    6    50   5    10   0.427[†](#tf3-2){ref-type="table-fn"}
   Sleeplessness                                    52        11     21         53   6    11   51   11   22   0.302
   Fatigue                                          52        12     23         53   8    15   51   13   25   0.395
   Mood changes                                     52        5      10         53   5    9    51   13   25   0.031
   Depressive tendencies                            52        4      8          53   6    11   51   5    10   0.818
  Skin and subcutaneous symptoms                                                                              
   Dry skin                                         52        6      12         53   4    8    51   6    12   0.726
   Allergic rash                                    52        4      8          53   5    9    51   7    14   0.584
   Redness                                          52        2      4          53   4    8    51   7    14   0.176[†](#tf3-2){ref-type="table-fn"}
   Eczema                                           51        3      6          53   4    8    51   5    10   0.814[†](#tf3-2){ref-type="table-fn"}
   Perianal itching                                 52        2      4          53   5    9    51   11   22   0.016
   Skin irritation                                  52        3      6          53   5    9    51   8    16   0.245
   Urticaria                                        52        1      2          52   3    6    51   3    6    0.634[†](#tf3-2){ref-type="table-fn"}
  Miscellaneous symptoms                                                                                      
   Sensitive to cold                                52        6      12         53   9    17   51   8    16   0.715
   Influenza                                        52        2      4          53   7    13   51   5    10   0.232[†](#tf3-2){ref-type="table-fn"}
   Hair loss                                        52        2      4          53   5    9    51   7    14   0.217[†](#tf3-2){ref-type="table-fn"}
   Bad breath                                       52        5      10         53   6    11   51   9    18   0.439
   Toothache                                        52        4      8          52   4    8    51   6    12   0.732[†](#tf3-2){ref-type="table-fn"}

Analyzed using chi-square test (4df).

Analyzed using Fisher\'s exact test when cells had counts \<5.

DISCUSSION
==========

In this study of obese knee OA patients, those who were assigned to the dietary intervention regained less weight over a 12-month period than did those assigned to the control group and to the exercise-based intervention. This finding confirms the feasibility of long-term weight loss maintenance in sedentary individuals, in this case patients with mobility limitations due to knee OA. However, no symptomatic superiority could be demonstrated, as the maintenance therapies were equally good on our primary outcome. Therefore, the effect of the run-in phase with a 16-week educational effort [@b24] appeared to last throughout the following year, whatever the subsequent group allocation. As a motivating factor, all participants had been promised a later resuming of the program (i.e., an invitation for further intervention after the first year (NCT00938808). This incentive could be a decisive difference from the data in our 1-year previous proof-of-concept study [@b41], demonstrating the effect of dietary intervention compared with no intervention. In the current study, the average decrease in pain on VAS from baseline was about 6 mm in all groups, corresponding to about 15%. The lack of group differences in symptoms, together with group differences in sustaining weight loss, contrasted with the anticipated weight loss dose-response relationship that would predict greater weight loss to yield greater symptom improvement [@b13].

Dietary intervention was superior to both control and exercise groups in maintaining weight loss. The rapid weight loss obtained by formula products is easy to enforce in a group-based setting [@b8], with participants in teams of 6 to 8 persons resulting in good compliance and a low dropout rate [@b12],[@b24],[@b41]--[@b43]. As a mandatory part of the program, the initial low-energy formula diet should be followed by a long-term lifestyle intervention program. The costs per participant of the full 16-week dietary intervention, including products and teaching in our setting, were only about £1,000 (approximately €1,170), and during the program the participants\' expenses for food were presumably low. In comparison, the exercise group was less successful at maintaining the weight loss. This finding is somewhat contrary to the general recommendations of exercise as a way of avoiding weight regain when applied in addition to continuous dietary control.

There are several possible explanations for the poorer weight loss maintenance in the exercise group. Firstly, the exercise program was designed to target knee OA pain and disability rather than high metabolic expenditure. The calories burned through exercise on a daily basis in this context are not significant enough to warrant extra foods or increased portion size. People dramatically overestimate the calories burned through exercise, so they must be reminded that the calories burned in 30 minutes of intensive exercise can be consumed in 30 seconds with an increased portion size or a simple chocolate bar. Furthermore, compliance with the facility-based parts of the exercise program was poor, and compliance with the home-based exercises was similarly poor, if not poorer. In spite of this poor compliance, there were no detectable differences between groups in the primary outcomes. Many of the participants in the exercise group expressed dissatisfaction with their group assignment, as they would have preferred continuous dietary consultations. This dissatisfaction could have affected both the primary and several of the secondary outcomes as well as compliance with the program. Although the neuromuscular exercise program used in the present study has been proved feasible for knee OA patients [@b44], the low compliance with the program precludes firm conclusions.

Despite differences in the loss of fat mass, there were no differences between the groups when comparing the (anticipated) reduction in lean body mass. Interestingly, the exercise group showed less increase in physical function on the SF-36 than did the 2 other groups, possibly because of that group\'s poor compliance with the program or dissatisfaction with allocation. Our results with the diet group are consistent with other trials using diets with low carbohydrates and high protein content for weight maintenance after a significant weight loss program [@b43]. According to the changes in fat mass, the dietary intervention group clearly had the most success, with an average loss of fat of about 9 kg, which was 3 kg more than the control group and close to twice as much as the exercise group.

In contrast to the present results, other studies have reported a superior effect of exercise on pain compared with diet in overweight patients with knee OA [@b45],[@b46]. However, these studies also corroborate one aspect of our study, as exercise per se did not cause weight loss [@b45]. It should be noted that a different study design was used, which was not comparable to our design\'s initial weight loss for all participants. Furthermore, questionnaires, both multi- and one-dimensional, create the problematic phenomenon of response shift (i.e., responders\' changing reference points, such as from being healthy to being more disabled) when people evaluate their own pain or function, thereby lacking temporal and contextual consistency [@b47]. This phenomenon could indicate that the participants in the present study tended to underestimate the effects of the treatment during the last year.

The present study recruited all patients with both obesity and knee OA, with no exceptions due to other medical conditions. Adverse effects were mild (not necessarily causal) and compliance with the dietary program was very high. Patients with knee OA are partially immobilized by pain, which leads to a lower energy expenditure, making weight loss particularly difficult. Often, patients with a combination of obesity and other chronic illnesses who have restricted ambulation are faced with this problem and self-selected low energy diets are very difficult to construct successfully. The present results of dietary advice that includes use of a formula weight loss diet confirm previous experiences with similar patient groups and substantiate the importance and necessity of a dietary lifestyle intervention strategy in this patient group. A simple reduction of ordinary food may prove deficient in vitamins and minerals; indeed, many of our participants were below reference range in vitamin D and B12 at baseline [@b48]. Sufficient supply of these vital food ingredients may be obtained from formula diets, which may be used in full or in part for periods to support and maintain weight loss.

The present study demonstrated no difference in effect of a dietary intervention or a specialized knee exercise program on knee symptoms in knee OA patients following an intensive weight loss. However, we found a more long-lasting effect on weight obtained with a dietary intervention, including the use of formula diet, group therapy, and education. This finding could suggest that patients with combined obesity and functional limitations precluding exercise participation may benefit from a dietary program alone [@b49]. The CAROT study differed somewhat from other large trials, such as the Arthritis, Diet, and Activity Promotion Trial (ADAPT) [@b50] and IDEA [@b46], which focused on diet, exercise, or both in combination. A common conclusion of all 3 trials is that diet is mandatory for weight loss, while exercise has been prescribed with varying compliance and effect. In the ADAPT and IDEA (effects of intensive diet and exercise on knee joint loads, inflammation, and clinical outcomes among overweight and obese adults with knee osteoarthritis) studies, clinical improvement in pain depended on the exercise.

As illustrated previously [@b13], on the basis of the changes in pain scores reported in the ADAPT study [@b50], the clinical efficacy can be documented only when weight loss is added to an exercise treatment. That was likely due to the fact that compared with the control group, the dietary intervention failed regarding both weight reduction and pain relief despite a significant within-group 16% pain reduction following 4.9% weight loss after 18 months of treatment [@b13]; interestingly, this recalls that the "exercise-only" group in the ADAPT study did not experience any significant pain reduction [@b13],[@b50]. This was not the case in the CAROT study, however. As indicated by the very low adherence to the program in the exercise group in the second phase, participants joined our program with the specific intent of losing weight on diet, not by exercising. The weight loss was successfully provided by diet alone in the run-in 16-week period and it may be suspected that the main part of the participants regarded the following year as time to pass before the majority were enrolled subsequently in the LIGHT trial (NCT00938808).

The interpretation of our results may well be that the psychological effect of being on a waiting list for dietary consultancy seems to be equally potent in maintaining a weight loss when compared to half-hearted efforts with exercise. This notion has some implication for planning of coming weight loss programs, which should consider regular followup programs or study extensions as means of maintenance.
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